Discontinued — last reported Q1 '20
A decrease typically indicates ongoing amortization or potential impairment charges, while an increase suggests new capitalizable investments or acquisitions related to the product line. Significant declines may signal a shortening of the product's remaining commercial life or competitive obsolescence.
This metric represents the carrying value of the Tysabri product-related intangible assets, net of accumulated amortizat...
Comparable to capitalized product rights or acquired intangible assets reported by other biopharmaceutical companies for specific drug franchises.
biib_segment_tysabri_product_finite_lived_intangible_assets_net